文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠-肝轴与肠道微生物群在健康与肝病中的作用

The gut-liver axis and gut microbiota in health and liver disease.

机构信息

Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA.

出版信息

Nat Rev Microbiol. 2023 Nov;21(11):719-733. doi: 10.1038/s41579-023-00904-3. Epub 2023 Jun 14.


DOI:10.1038/s41579-023-00904-3
PMID:37316582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10794111/
Abstract

The trillions of microorganisms in the human intestine are important regulators of health, and disruptions in the gut microbial communities can cause disease. The gut, liver and immune system have a symbiotic relationship with these microorganisms. Environmental factors, such as high-fat diets and alcohol consumption, can disrupt and alter microbial communities. This dysbiosis can lead to dysfunction of the intestinal barrier, translocation of microbial components to the liver and development or progression of liver disease. Changes in metabolites produced by gut microorganisms can also contribute to liver disease. In this Review, we discuss the importance of the gut microbiota in maintenance of health and the alterations in microbial mediators that contribute to liver disease. We present strategies for modulation of the intestinal microbiota and/or their metabolites as potential treatments for liver disease.

摘要

肠道中的万亿微生物是健康的重要调节剂,肠道微生物群落的紊乱会导致疾病。肠道、肝脏和免疫系统与这些微生物有着共生关系。环境因素,如高脂肪饮食和饮酒,会破坏和改变微生物群落。这种生态失调会导致肠道屏障功能障碍、微生物成分易位到肝脏以及肝病的发生或进展。肠道微生物产生的代谢物的变化也可能导致肝病。在这篇综述中,我们讨论了肠道微生物群在维持健康中的重要性,以及微生物介质的改变如何导致肝病。我们提出了调节肠道微生物群和/或其代谢物的策略,作为治疗肝病的潜在方法。

相似文献

[1]
The gut-liver axis and gut microbiota in health and liver disease.

Nat Rev Microbiol. 2023-11

[2]
aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota.

Microbiol Spectr. 2024-4-2

[3]
Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?

Expert Rev Gastroenterol Hepatol. 2015

[4]
Dysbiosis and liver diseases (Review).

Int J Mol Med. 2021-9

[5]
The Immune System through the Lens of Alcohol Intake and Gut Microbiota.

Int J Mol Sci. 2021-7-13

[6]
The gut-liver axis in liver disease: Pathophysiological basis for therapy.

J Hepatol. 2020-3

[7]
The gut microbiota-bile acid axis in cholestatic liver disease.

Mol Med. 2024-7-19

[8]
Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.

J Gastroenterol Hepatol. 2023-7

[9]
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle.

Pharmacol Ther. 2022-3

[10]
Contribution of gut microbiota to drug-induced liver injury.

Hepatobiliary Pancreat Dis Int. 2023-10

引用本文的文献

[1]
Gut-Microbiome and Nutritional Analysis Reveals Food Intake as a Key Factor in the Incidence and Prevention of Colon Polyps: A Cross-Sectional Study.

Health Sci Rep. 2025-8-26

[2]
Genomic Alterations and Microbiota Crosstalk in Hepatic Cancers: The Gut-Liver Axis in Tumorigenesis and Therapy.

Genes (Basel). 2025-7-30

[3]
Combined Impacts of Acute Heat Stress on the Histology, Antioxidant Activity, Immunity, and Intestinal Microbiota of Wild Female Burbot () in Winter: New Insights into Heat Sensitivity in Extremely Hardy Fish.

Antioxidants (Basel). 2025-7-31

[4]
Crosstalk Between Microbiome and Ferroptosis in Diseases: From Mechanism to Therapy.

Compr Physiol. 2025-8

[5]
Mucosal microbiota signatures reveal diagnostic insights in chronic liver disease.

BMC Gastroenterol. 2025-8-21

[6]
Bioartificial liver: Where lies the path ahead-A review.

Hepatol Commun. 2025-8-15

[7]
The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy.

Front Microbiol. 2025-7-30

[8]
Lactiplantibacillus plantarum attenuate gossypol-induced hepatic lipotoxicity by altering intestinal microbiota for enriching microbial tryptophan metabolites in Nile tilapia (Oreochromis niloticus).

Microbiome. 2025-8-4

[9]
Dietary intervention with Polygonatum sibiricum polysaccharides mitigates cadmium liver toxicity: a gut-liver axis perspective.

Front Nutr. 2025-7-16

[10]
Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer.

Cancer Cell Int. 2025-7-29

本文引用的文献

[1]
Comparison of LED and LASER Colonoscopy About Linked Color Imaging and Blue Laser/Light Imaging of Colorectal Tumors in a Multinational Study.

Dig Dis Sci. 2023-10

[2]
Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism.

Biomed Pharmacother. 2023-3

[3]
Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.

Hepatology. 2023-6-1

[4]
Inulin intervention attenuates hepatic steatosis in rats via modulating gut microbiota and maintaining intestinal barrier function.

Food Res Int. 2023-1

[5]
Postbiotics Prepared Using CCFM1224 Prevent Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Liver Metabolism.

Int J Mol Sci. 2022-11-4

[6]
Microbiome-derived ethanol in nonalcoholic fatty liver disease.

Nat Med. 2022-10

[7]
Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases.

Nat Med. 2022-9

[8]
Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes.

Cell. 2022-8-18

[9]
Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients.

Cell Mol Biol (Noisy-le-grand). 2022-2-28

[10]
Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.

Front Cell Infect Microbiol. 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索